PD0176078

• CAT Number: I013302
• CAS Number: 248922-46-5
• Molecular Formula: C₂₃H₃₀F₂N₂O
• Molecular Weight: 388.49
• Purity: ≥95%
• Target: Neuronal Signaling
• Solubility: DMSO
• IUPAC Name: (2S)-N-[4,4-bis(4-fluorophenyl)butyl]-4-methyl-2-(methylamino)pentanamide
• InChI: InChI=1S/C23H30F2N2O/c1-16(2)15-22(26-3)23(28)27-14-4-5-21(17-6-10-19(24)11-7-17)18-8-12-20(25)13-9-18/h6-13,16,21-22,26H,4-5,14-15H2,1-3H3,(H,27,28)/t22-/m0/s1
• InChIKey: QGJKMAIASNMXFI-QFIPXVFZSA-N
• SMILES: CC(C)C[C@@H](C(=O)NCCCC(C1=CC=C(C=C1)F)C2=CC=C(C=C2)F)NC

PD0176078（Cat No.:I013302）is a selective inhibitor of the protein kinase JAK2 (Janus kinase 2), which plays a crucial role in various cellular processes, including immune response and hematopoiesis. By inhibiting JAK2, PD0176078 can modulate signaling pathways involved in cytokine receptor activation, which is relevant in treating diseases associated with abnormal JAK2 activity, such as certain cancers and autoimmune disorders. PD0176078 has shown potential in preclinical studies for its ability to reduce tumor growth and inflammation, and ongoing research aims to assess its safety, efficacy, and therapeutic applications in clinical settings.

Reference

[1]. TakashiYamamoto, et al. Discovery, structure-activity relationship study, and oral analgesic efficacy of cyproheptadine derivatives possessing N-type calcium channel inhibitory activity. Bioorg Med Chem. 2006 Aug 1;14(15):5333-9.